LANXESS successfully places EUR 500 million benchmark bond

Cologne

The specialty chemicals company LANXESS has successfully placed a 6-year-tenor euro benchmark bond with a coupon of 0.0 percent in the European capital market. LANXESS will use the funds to finance the planned acquisition of the microbial control business of US-based chemical company IFF.

The new bond is listed on the Luxembourg Stock Exchange in denominations of EUR 1,000.

“We have secured a first step of financing already quickly after the announcement of the acquisition of IFF Microbial Control and are happy about the very receptive reaction of the capital market to our offering,” said LANXESS Chief Financial Officer Michael Pontzen.

LANXESS' issuer ratings are currently Baa2 (Moody’s), BBB (Standard & Poor’s) and BBB+ (Scope). A bank consortium of active joint bookrunners comprising Citi, Société Générale and Unicredit was mandated to place the bond.

Information for editors:
All global LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com.
Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

 

MORE ABOUT THIS TOPIC

PRESS RELEASE
Since August 1, 2013, specialty chemicals Group LANXESS is steering its global business from the LANXESS Tower in Cologne.

LANXESS starts fiscal year 2025 with significant earnings increase

May 08, 2025
PRESS RELEASE
Glass bottles with fragrances

LANXESS to showcase aroma chemicals at SIMPPAR 2025

May 06, 2025
PRESS RELEASE
LANXESS corporate headquarters in Cologne

Top ratings for LANXESS: CDP recognizes commitment to climate and water protection

April 22, 2025
PRESS RELEASE
Since August 1, 2013, specialty chemicals Group LANXESS is steering its global business from the LANXESS Tower in Cologne.

LANXESS completes sale of its Urethane Systems business to UBE Corporation

April 09, 2025
PRESS RELEASE
Messestand auf der Kosmetikmesse Gobal in Paris 2024

LANXESS presents portfolio for cosmetics and personal care at the in-cosmetics Global

April 04, 2025